Jia Mei

Jia Mei

Auto-generated profile, based on publicly available information

Jia Mei

TUM University Hospital Klinikum rechts der Isar, Munich, Germany

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2026 in Cancer Research
Verified
Journal Article
Open access
LLLaura Leonhardt
Laura Leonhardt
JMJia Mei
Jia Mei
AHAudrey M. Hendley
Audrey M. Hendley
SASuhail A. Ansari
Suhail A. Ansari
SASudipta Ashe
Sudipta Ashe
MHMatthias Hebrok
Matthias Hebrok
Aberrant epigenetic regulation is a central driver of tumorigenesis, and the reversibility of epigenetic modifications underscores their potential as therapeutic targets. Epigenetic factors often function in a highly context-dependent manner, necessitating rigorous study of their dynamic and complex roles. In this study, we uncovered an intricate regulation of tumor development and plasticity by the KDM6 family of histone demethylases in pancreatic ductal adenocarcinoma (PDAC), a disease with sustained high mortality and limited treatment options. Temporally resolving KRAS-driven tumor development revealed a switch from tumor-suppressive to oncogenic functions for KDM6B, with implications for tumor aggressiveness in rodents and patients. These oncogenic functions were mediated by regulation of NOTCH signaling, a pathway known to promote PDAC tumorigenesis. Concurrent elimination of KDM6A and KDM6B led to profound phenotypic changes resembling sarcomatoid carcinomas, a rare, poorly characterized subtype of human PDAC. These tumors exhibited altered oncogenic networks, including NOTCH and c-Jun N-terminal kinase signaling, that may support the development of therapies tailored to molecular subtypes. Given the critical and distinct activities of KDM6 histone demethylases during PDAC development, targeting KDM6 activities may be beneficial in the right cellular and temporal context. Significance: Histone demethylases KDM6A and KDM6B dynamically modulate pancreatic cancer development, aggressiveness, and plasticity by altering NOTCH signaling, providing a rationale for developing selective KDM6 inhibitors.